The Association of Intravitreal Injections of Different Anti-Vascular Endothelial Growth Factor with Systemic Outcomes in Diabetic Patients
Journal of Personalized Medicine · 18.03.2023 · 13 (3) · 544
DOI: 10.3390/jpm13030544 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 18.03.2023. Verfasst von Eugene Yu-Chuan Kang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan 333, Taiwan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, Linkou Chang Gung Memorial Hospital.
Abstract (Originalsprache)
This retrospective cohort study aimed to assess the systemic effects of three commonly available anti-vascular endothelial growth factor intravitreal injections in patients with diabetes, using data taken from a multi-institutional database in Taiwan. Patient data were sourced from the multi-institutional Chang Gung Research Database. Participants were divided into groups based on treatment with bevacizumab, ranibizumab, or aflibercept. Baseline characteristics were matched among the groups by the inverse probability of treatment weighting. The incidence rate of outcome events was calculated as the number of events divided by 100 person-years of follow-up. The cumulative incidence function was used to estimate the incidence rate of the outcome events among groups. The incidence of ischemic stroke was higher in the ranibizumab group than the bevacizumab and aflibercept groups (1.65, 0.92, and 0.61 per 100 person-years, respectively). The incidence of major adverse lower-limb events was higher in the bevacizumab group (2.95), followed by ranibizumab (2.00) and aflibercept (0.74). Major bleeding was relatively higher in bevacizumab (12.1) compared to ranibizumab (4.3) and aflibercept (3.8). All-cause death was higher for both bevacizumab (3.26) and aflibercept (2.61) when compared to ranibizumab (0.55), and all-cause admission was found to be highest with bevacizumab (58.6), followed by aflibercept (30.2), and ranibizumab (27.6). The bevacizumab group demonstrated a greater decrease in glycated hemoglobin compared to the baseline level (−0.33%). However, a few differences in the clinical condition between the groups were still observed after matching. In conclusion, this study suggests that different anti-vascular endothelial growth factor agents may be associated with various and differing systemic adverse events. The differences might also be attributed to differences in patient characteristics and clinical status.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan 333, Taiwan.
- College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
- Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan 333, Taiwan.
- Department of Education, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan 333, Taiwan.
- MidAtlantic Retina, The Retina Service of Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA 19107, USA.
- Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, NY 10032, USA.
ORCID-Profile: Eugene Yu-Chuan Kang, Tzu-Yi Lin, Nan-Kai Wang, Ming-Jen Chan, Kuan-Jen Chen
Förderung
- NEI NIH HHS
- Linkou Chang Gung Memorial Hospital
Zitieren
APA
Kang, E. Y., Lin, T. Y., Garg, S. J., Wang, N. K., Chen, L. J., Huang, P. W., Chan, M. J., Chen, K. J., Wu, W. C., Lai, C. C., & Hwang, Y. S. (2023). The Association of Intravitreal Injections of Different Anti-Vascular Endothelial Growth Factor with Systemic Outcomes in Diabetic Patients. Journal of Personalized Medicine, 13(3), 544. https://doi.org/10.3390/jpm13030544
Vancouver
Kang EY, Lin TY, Garg SJ, Wang NK, Chen LJ, Huang PW, et al. The Association of Intravitreal Injections of Different Anti-Vascular Endothelial Growth Factor with Systemic Outcomes in Diabetic Patients. Journal of Personalized Medicine. 2023;13(3):544. doi:10.3390/jpm13030544
BibTeX
@article{Kang2023,
author = {Kang, Eugene Yu-Chuan and Lin, Tzu-Yi and Garg, Sunir J and Wang, Nan-Kai and Chen, Lee-Jen and Huang, Pei-Wei and Chan, Ming-Jen and Chen, Kuan-Jen and Wu, Wei-Chi and Lai, Chi-Chun and Hwang, Yih-Shiou},
title = {The Association of Intravitreal Injections of Different Anti-Vascular Endothelial Growth Factor with Systemic Outcomes in Diabetic Patients},
journal = {Journal of Personalized Medicine},
year = {2023},
volume = {13},
number = {3},
pages = {544},
doi = {10.3390/jpm13030544}
}
EUVIMED